Objective: Malignant ovarian tumours are diagnosed at an advanced stage in the majority of cases. However, only a small percentage present as extra-abdominal, non-lymph-node solid metastases, as in the breast, and they are usually cases of relapse. The discovery of mono- or bilateral breast lesions with peritoneal carcinosis and/or abdomino-pelvic lesions can be cumbersome in the differential diagnosis of primary tumours. This article aims to summarize current evidence on the detection of breast metastases at diagnosis of ovarian cancer.
Study Design: A systematic review of the literature in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including case reports and case series, was undertaken. Data regarding study features; population characteristics; clinical, radiological and histological assessment of the disease; treatment and follow-up were collected. In addition, a case report of a patient managed at the authors' centre is provided.
Results: According to the search strategy, 16 articles (18 patients) were included in this review. Serous ovarian, fallopian tube or primary peritoneal cancer was detected in 61% of cases, while another type or a non-specified type of epithelial ovarian cancer was detected in 27.7% of cases; there was one case with granulosa cell tumour of the ovary and one case with mucinous ovarian tumour of low malignant potential. Breast metastases were mainly monolateral (66.6%), with other extra-abdominal sites of disease in the majority of the cases. A minority of patients (16.6%) received treatment for primary breast cancer with a subsequent diagnosis of ovarian cancer. Concomitant breast and abdominal surgery can be an option. PAX8, WT1 and CA125 immunohistochemical staining can aid in differential diagnosis.
Conclusion: Breast metastases of malignant ovarian tumours must be promptly recognized to ensure proper treatment. Specific immunohistochemical analysis can be a decisive assessment in uncertain cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejogrb.2020.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bone-Induced Her2 Promotes Secondary Metastasis in HR+/Her2- Breast Cancer.
Cancer Discov
January 2025
Icahn School of Medicine at Mount Sinai, New York, United States.
Bone metastases can disseminate to secondary sites and promote breast cancer progression creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of Her2-expressing (Her2E) circulating tumor cells (CTCs) after analyzing over 13,000 CTCs from a cohort of 137 metastatic breast cancer (MBC) patients with initial HR+/Her2- status and employ preclinical models of bone metastasis (BM) to validate the role of Her2E CTCs in multi-organ metastases.
View Article and Find Full Text PDFSyngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases.
Elife
January 2025
Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors.
View Article and Find Full Text PDFUtilizing machine-learning techniques on MRI radiomics to identify primary tumors in brain metastases.
Front Neurol
January 2025
Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Objective: To develop a machine learning-based clinical and/or radiomics model for predicting the primary site of brain metastases using multiparametric magnetic resonance imaging (MRI).
Materials And Methods: A total of 202 patients (87 males, 115 females) with 439 brain metastases were retrospectively included, divided into training sets (brain metastases of lung cancer [BMLC] = 194, brain metastases of breast cancer [BMBC] = 108, brain metastases of gastrointestinal tumor [BMGiT] = 48) and test sets (BMLC = 50, BMBC = 27, BMGiT = 12). A total of 3,404 quantitative image features were obtained through semi-automatic segmentation from MRI images (T1WI, T2WI, FLAIR, and T1-CE).
Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India.
Cureus
December 2024
Medical Affairs, Zydus Lifesciences, Ahmedabad, IND.
Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a highly aggressive subtype characterized by a high recurrence rate. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, has shown improved outcomes; however, its effectiveness in cases with brain metastases remains unclear. The T-DM1 biosimilar has emerged as a cost-effective treatment option.
View Article and Find Full Text PDFPrimary apocrine adenocarcinoma, a rare malignancy, is an aggressive tumor rarely reported. It has diagnostic and treatment challenges as it is difficult to distinguish it from metastases due to breast carcinoma. Currently, no data are available for the use of next-generation sequencing to identify the possibility of targeted therapies for metastatic disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!